Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYTRUDA + Lenvima vs KEYTRUDA + lenvatinib placebo in first-line PD-L1-positive metastatic NSCLC (China)
CTR20191589Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Aug 2019; status: terminated.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191589.